
Sign up to save your podcasts
Or


In an astonishing story of a scientific discovery, Greg Winter tells Jim Al-Khalili how decades of curiosity-driven research led to a revolution in medicine.
Forced to temporarily abandon his work in the lab when a road rage incident left him with a paralysed right arm, Greg Winter spent several months looking at the structure of proteins. Looking at the stunning computer graphics made the pain in his arm go away. It also led him to a Nobel Prize winning idea: to ‘humanise’ mouse antibodies. A visit to an old lady in hospital made Greg determined to put his research to good use. He fought hard to ensure open access to the technology he invented and set up a start up company to encourage the development of therapeutic drugs. It took years to persuade anyone to fund his Nobel Prize winning idea that led to the creation of an entirely new class of drugs, known as monoclonal antibodies. In 2018, the market for these drugs, which include Humira for rheumatoid arthritis and Herceptin for breast cancer, was worth $70 billion.
By BBC World Service4.4
940940 ratings
In an astonishing story of a scientific discovery, Greg Winter tells Jim Al-Khalili how decades of curiosity-driven research led to a revolution in medicine.
Forced to temporarily abandon his work in the lab when a road rage incident left him with a paralysed right arm, Greg Winter spent several months looking at the structure of proteins. Looking at the stunning computer graphics made the pain in his arm go away. It also led him to a Nobel Prize winning idea: to ‘humanise’ mouse antibodies. A visit to an old lady in hospital made Greg determined to put his research to good use. He fought hard to ensure open access to the technology he invented and set up a start up company to encourage the development of therapeutic drugs. It took years to persuade anyone to fund his Nobel Prize winning idea that led to the creation of an entirely new class of drugs, known as monoclonal antibodies. In 2018, the market for these drugs, which include Humira for rheumatoid arthritis and Herceptin for breast cancer, was worth $70 billion.

7,639 Listeners

876 Listeners

1,046 Listeners

5,520 Listeners

1,799 Listeners

1,763 Listeners

1,049 Listeners

1,979 Listeners

599 Listeners

766 Listeners

90 Listeners

407 Listeners

410 Listeners

821 Listeners

757 Listeners

731 Listeners

217 Listeners

366 Listeners

476 Listeners

238 Listeners

3,177 Listeners

720 Listeners

113 Listeners

1,002 Listeners